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Background: Treatment effectiveness of Helicobacter pylori varies regionally and is decreasing worldwide, principally
as a result of antibiotic resistant bacterium. Tetracycline is generally included in second line H. pylori eradication
regimens. In Brazil, a high level of tetracycline resistance (TetR) is mainly associated with AGA926-928TTC 16 S rDNA
nucleotide substitutions. As H. pylori culture is fastidious, we investigated the primary occurrence of H. pylori 16 S
rDNA high level TetR genotype using a molecular approach directly on gastric biopsies of dyspeptic patients
attending consecutively at Hospital das Clinicas of Marilia, São Paulo, Brazil.
Methods: Gastric biopsy specimens of 68 peptic ulcer disease (PUD) and 327 chronic gastritis (CG) patients with a
positive histological diagnosis of H. pylori were investigated for TetR 16 S rDNA genotype through a molecular assay
based on amplification of a 16 S rDNA 545 bp fragment by polymerase chain reaction and HinfI restriction
fragment length polymorphism (PCR/RFLP). Through this assay, AGA926-928TTC 16 S rDNA TetR genotype resulted
in a three DNA fragment restriction pattern (281, 227 and 37 bp) and its absence originated two DNA fragments
(264 and 281 bp) due to a 16 S rDNA conserved Hinf I restriction site.
Results: The 545 bp 16 S rDNA PCR fragment was amplified from 90% of gastric biopsies from histological H. pylori
positive patients. HinfI RFLP revealed absence of the AGA926–928TTC H. pylori genotype and PCR products of two
patients showed absence of the conserved 16 S rDNA HinfI restriction site. BLASTN sequence analysis of four
amplicons (two conserved and two with an unpredicted HinfI restriction pattern) revealed a 99% homology to H.
pylori 16 S rDNA from African, North and South American bacterial isolates. A nucleotide substitution abolished the
conserved HinfI restriction site in the two PCR fragments with unpredicted HinfI RFLP, resulting in an EcoRI
restriction site.
Conclusions: H. pylori AGA926-928TTC 16 S rDNA gene substitutions were not found in our population. More
research is required to investigate if H. pylori TetR has a different genetic background in our region and if the
nucleotide substitutions of the uncultured H. pylori 16 S rRNA partial sequences have biological significance.
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It is widely accepted that Helicobacter pylori, a Gram
negative microaerophilic bacterium, is associated with
several digestive tract diseases such as chronic gastritis,
peptic and duodenal ulcers, gastric cancer and lympho-
proliferative disorders [1]. There is no standardized
treatment regimen for H.pylori infection [2] and once
the bacterium is detected in altered gastric mucosa, the
indicated treatment consists of a triple antibiotic regi-
men including metronidazole, clarithromycin, amoxicil-
lin, tinidazole, tetracycline and fluoroquinolones
associated with a proton pump inhibitor such as ome-
prazole, lansoprazole or pantoprazole [3-5], according to
antibiotic prescription policies for local medical care.
H. pylori eradication rates with a number of combined
agents and regimens are close to 80% [6,7], varying from
country to country and regionally within countries [8].
Several factors contribute to this low rate of H. pylori
healing including the inefficiency of the antibiotic pene-
tration in the gastric mucosa, inactivation of the anti-
biotic by the acid secretion of the stomach [9], lack of
patient compliance [10] and principally, emergency cases
and increase in H. pylori antibiotic resistant strains [11].
Thus, regional H. pylori resistance surveillance is of
great importance for test and treatment strategies.
In Brazil, a country of continental dimensions, the ma-
jority of practicing clinicians include tetracycline in a
second line treatment regimen after failure of the clas-
sical triple regimen composed of claritromycin, amoxicil-
lin and a proton pump inhibitor for seven days to
overcome H. pylori infection [12].
H. pylori resistance to tetracycline (TetR) is low in
most countries [13-15], conversely, in Latin America,
according to a small number of studies, it has been
shown to be high in Chile [16] and in Brazil [17]. More-
over, for some years the incidence of TetR has been in-
creasing [15,18-21]. Accordingly, considering the clinical
importance of primary H. pylori resistance to antibiotics,
it should be considered regionally before being included
in eradication regimens.
The gold standard method for determination of H.
pylori in vitro susceptibility to antibiotics corresponds
to the isolation of the microorganism by culture.
However, because of the slow growth and the particu-
lar requirements of H. pylori culture, this approach is
not reliable for use in most routine clinical laborator-
ies, principally in developing countries. Hence, mo-
lecular tests targeting resistance associated gene
mutations directly from biopsy specimens have the
potential for use in large scale studies [22-25].
The molecular mechanism of TetR consists of its binding
to a specific 16 S rRNA region, interacting stoically with
the aminoacyl-tRNA transferase to the A site of the ribo-
some. This binding site has been defined by atomicresolution in ribosomes of Thermus thermophilus being
formed by two domains of the 16 S rRNA fraction consist-
ing of helix 34 and the loop next to helix 31 [26,27]. In H.
pylori isolates, the high degree of TetR is mainly due to
three base mutations, from AGA926-928 to TTC, in the
16 S rRNA genes rrnA/B [28,29]. Mutations in one or two
of these positions result in a low level of TetR [30,31].
In Brazil, studies performed on patients from Bragança
Paulista, São Paulo, showed that triple AGA926-928 to
TTC mutations are found in all TetR H. pylori isolates
[32]. Thus, using a molecular approach based on a poly-
merase chain reaction associated with restriction frag-
ment length polymorphism (PCR-RFLP) assay, we
investigated the primary incidence of H. pylori high level
TetR directly in gastric biopsy specimens obtained from
dyspeptic patients submitted to gastroscopy at Hospital
das Clinicas of Marilia, São Paulo, Brazil, from January
2003 to July 2006.
Results and discussion
Gastric disease outcome of 1102 patients attending
the gastroenterology outpatient clinic of Hospital das
Clínicas of Marília was investigated by endoscopy and
histopathology. Endoscopic finding of peptic or duodenal
ulcer disease (PUD) were present in 119 patients. Different
degrees of chronic gastritis (CG) were observed by histo-
pathology in 693 patients and other alterations correspond-
ing mostly to gastroesophageal reflux disease (GERD) and
normal gastric mucosa, were found in 290 patients. Some
patients presented more than one alteration, with the most
severe pathology being considered in the analysis.
Detection of H. pylori was performed directly from bi-
opsy specimens by histology, the gold standard H. pylori
diagnostic test employed in our clinical routine which
together with histopathological analysis is used to decide
for H. pylori eradication therapy. Of 119 PUD, 693 CG
and 290 GERD samples, 76, 359 and 2, respectively, were
positive for H. pylori by histology.
Once detected in gastric mucosa, a classical H.
pylori eradication triple regimen is prescribed in our
gastroenterology health care clinics. When first
choice regimen therapy fails to eradicate H. pylori, a
second line regimen containing tetracycline is the
most indicated. H. pylori antibiotic TetR varies re-
gionally, being very low in Europe and North America
[2,33,34]. However, in Asia [15,19,35] and Latin America,
including Brazil [16,32], a high rate of H. pylori TetR has
been found. Thus, in order to improve the choice of
H. pylori associated disease therapy, principally in
case of first eradication failure, we investigated the re-
gional high level of H. pylori TetR using a molecular
approach based on PCR and RFLP directly from the
same gastric biopsy used for rapid urease test. Only
biopsy samples from the patients with positive H.
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H. pylori 16SrDNA PCR fragment was obtained from
89.5% (68/76) and 91.1% (327/359) of gastric biopsies
from PUD and CG patients, respectively. As both
tests were performed on a single and different gastric
biopsy and H. pylori infection presents a focal charac-
teristic of infection [36], to improve sensitivity of this
method, multiple biopsy sampling is recommended.
Sequentially, in order to detect the major related point
mutations, AGA to TTC at the positions 926, 927 and 928
of the H. pylori 16 S rDNA associated with a high level of
TetR, and a unique genotype characterized in Brazilian
TetR H. pylori isolates [32], the 545 bp 16 S rDNA PCR
fragment was restricted with HinfI. In this H. pylori 16 S
rDNA amplicon there is a conserved HinfI restriction site,
which provides an internal control of enzyme digestion,
resulting in a two DNA fragment restriction pattern, when
the triple AGA926-928TTC nucleotide substitution is ab-
sent. Of 395 PCR samples, 393 presented the two DNA
fragment restriction pattern and two PCR products
obtained from a PUD (Hp16S563Mar) patient and a CG
(Hp16S587bp) patient were not digested by HinfI. The
high tetracycline resistant AGA926-928TTC genotype
dependent on H. pylori 16 S rDNA was not present in our
population. These results can be indicative of H. pylori
high level TetR absence or that in our region other 16 S
rDNA nucleotide substitutions or different genetic factors
are involved in tetracycline resistance, as found by other
studies [21]. More research has to be carried out to con-
firm or exclude these hypotheses.
In order to confirm the specificity of the 545 bpH.
pylori 16 S rDNA PCR products amplified from gas-
tric biopsies, the 545 bp PCR fragments obtained
from two H. pylori positive PUD patients used as
controls in PCR reactions (Hp16S248Mar and
Hp16S644Mar), and the 545 bp PCR fragments with
unpredicted HinfI restriction pattern named
Hp16S563Mar and Hp16S587bp, were sequenced and
analyzed by basic BLASTN search [37]. All four
sequences presented 99% homology to the 16 S rDNA
from West and South African, South and North
American H.pylori isolates. The point mutations
found in each analyzed PCR sequence compared to
the H. pylori 16 S rDNA reference sequences present-
ing higher homology to the obtained amplicons are
summarized in Table 1. Abolishment of the HinfI re-
striction site of Hp16S563 and 587Mar resulted from
a nucleotide substitution at position 958, originating
in an EcoRI restriction site. Thus, the nucleotide sub-
stitutions in these 16 S 545 bp PCR fragments were
confirmed by EcoRI restriction analysis (data not
shown). The biological significance of nucleotide sub-
stitutions found in our 16 S uncultured H. pylori PCR
fragments needs to be investigated.Conclusions
The high level TetR H. pylori genotype dependent on
AGA926-929TTC 16 S rDNA gene substitutions was
not found in our population. More research is required
to investigate if H. pylori high rate TetR is absent or if it
is associated with a different bacterial genetic back-
ground in our region. Also, the biological significance of
the unpredicted nucleotide substitutions of the Marilia




1102 adult patients resident in Marilia city, São Paulo
State, Brazil, aged 19 to 91 years, who had consecutively
undergone esophagogastroduodenoscopy (EGD) for
upper abdominal pain or dyspeptic symptoms from
January 2003 through July 2006 at the gastroenterology
outpatient clinic of the Hospital das Clínicas of Marília
Medical School, were enrolled in this study.
Endoscopy, biopsies
The EGD was accomplished by fibroendoscope (GIF-
XP20, GIF-XQ20) or video-endoscope (GIF-100) both
from Olympus. Gastric or duodenal ulcer diagnosis was
defined by endoscopy and two fragments of the antrum
were collected to perform the rapid urease and histo-
pathological tests. The biopsy used for the rapid urease
test was further submitted to DNA extraction. The
protocol used is in agreement with the Helsinki Declaration
and was approved by the Ethical Committee in Human Re-
search from Marilia Medical School, under reference num-
ber 388/01.
Histology
One antral specimen was fixed in formol solution at
10% and embedded in paraffin. Sections were Giemsa
stained for H. pylori evaluation and were stained with
hematoxilin and eosin for assessment of histopathologic
alterations [38].
DNA extraction and Polymerase chain reaction
Polymerase chain reaction and restriction analysis were
set up with the same biopsy used for the rapid urease
test. This was submitted to DNA extraction with the em-
ployment of the GFx DNA extraction kit purchased from
Amersham/Pharmacia Biotech, following the manufac-
turer’s instructions. DNA was quantified in agarose gel elec-
trophoresis using the Invitrogem low mass ladder and
50-100ηg were used in the PCR reactions with the
primer set Hp16Sr1 (sense),): 50 AAC ATT ACT GAC
GCT GAT TG 30; Hp16S r2 (antisense): 50 TGG CTC
CAC TTC GCA GTA TT 30, which amplify a con-
served fragment of 545 bp corresponding to the H.
Table 1 Comparison of Helicobacter pylori 545 bp 16 S rDNA nucleotide polymorphisms among references and
uncultured bacterium strains
H. pylori strain+ 16 S rDNA nucleotide positions#
926-928 947 954-959 981 988 1092 1093 1097
SouthAfrica07 AGA A GAATCC A T T C G
2017WestAfrica AGA A GAATCC A T T C G
EU544200USA AGA A GAATCC A T T T G
Puno/Peru AGA A GAATCC G C T C G
Hp16S248Mar AGA G GAATCC A T T C A
Hp16S644Mar AGA A GAATCC A T G C G
Hp16S563Mar AGA A GAATTC A T T T G
Hp16S587Mar AGA A GAATTC G C T C G
# based on H. pylori reference strain 26995; + accession numbers of the H. pylori sequence strains for SouthAfrica07, 2017WestAfrica, EU544200USA, Puno/Peru,
Hp16S248Mar, Hp16S644mar, Hp16S563Mar and Hp16S567Mar are, respectively: [Genbank:CP002336.1, Genbank:CP002571.1, Genbank:EU544200.1, Genbank:
CP002982.1, Genbank:JQ315410, Genbank:JQ315411, Genbank:JQ315412 and Genbank:JQ315413].
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700 and 1245 (numbered according to the rrnA gene
of H. pylori strain 26695), modified from [32]. In all
PCR reactions a negative and a positive control were used
corresponding to, respectively, sterile water and two dif-
ferent urease H. pylori positive gastric biopsies from PUD
patients. PCR condition was 94°C 50 followed by 40 cycles
of 94°C 10/55°C 10/72°C 10 and one cycle at 72°C 70, with a
total volume of 25 μl containing 1x PCR buffer, 200 μM
dNTPs, 2.0 mM MgCl2, 1μM oligoHp16Sr1, 1μM oligo
Hp16Sr2, 1.25 U Taq DNA Polymerase Platinum Brazil
(Invitrogen), 2.5% DMSO, 50ηg DNA. The PCR products
were resolved in 1.5% agarose gels stained with ethidium
bromide and photographed under UV light.Restriction and sequencing analysis
The 16 S rDNA 545 bp amplicons obtained by PCR
from biopsy specimens were digested with Hinf I (biolab
– New England) according to the manufacturer’s
instructions. The predictable restriction pattern for
tetracycline susceptible H. pylori strains corresponds to
two fragments of 264 and 281 bp and for H. pylori
strains with high tetracycline resistance corresponds to
three fragments of 281, 227 and 37 bp. The products of
restriction analysis were resolved in 8% acrylamide gels,
stained with ethidium bromide and photographed under
UV light. 16 S rRNA 545 bp PCR amplicons from the
two H. pylori positive control gastric biopsies
(Hp16S248Mar and 644Mar) and the two amplicons
presenting unexpected Hinf I restriction patterns
(Hp16S563Mar and Hp16S587bp) were submitted to se-
quencing with DyeTM Terminator v3.0 cycle Sequen-
cing Ready Reaction kit and an ABI-3100 machine
purchased from Applied Biosystem, according to the
manufacturer’s instructions. Nucleotide sequence deter-
mination was performed in duplicate and comparativeanalysis was carried out by basic nucleotide BLAST
alignment [37].
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